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CD158K/KIR3DL2 Transcript Detection in Lesional
Skin of Patients with Erythroderma Is a Tool for the
Diagnosis of Se´zary Syndrome
Nicolas Ortonne1,2,3,6, Sabine Le Gouvello2,3,4,6, Hicham Mansour4, Catherine Poillet4, Nadine Martin1,3,
Marie-He´le`ne Delfau-Larue3,4, Karen Leroy1,3, Jean-Pierre Farcet3,4, Martine Bagot2,3,5 and Armand
Bensussan2,3
The distinction between Se´zary syndrome (SS) and benign erythrodermic inflammatory diseases (EID) is
difficult to make both clinically and on skin biopsies, since histomorphology can provide nonspecific results.
New markers of circulating malignant Se´zary cells have been recently described, especially CD158k/KIR3DL2
and T-plastin, but it has not been yet determined whether they could help in the diagnosis of erythroderma in
skin samples. In this study, 13 frozen skin specimens from 10 SS patients and 26 from EID were analyzed for
CD158k/KIR3DL2 expression using immunohistochemistry with AZ158 mAb, which also recognizes the
monomeric CD158e/KIR3DL1 receptor. Although positive in all SS samples, immunohistochemistry appeared
to not reliably discriminate between SS and EID. Therefore in all samples disclosing a significant staining with
AZ158 mAb, CD158k/KIR3DL2, CD158e/KIR3DL1 and T-plastin mRNA expression were analyzed on the same skin
specimen using conventional and/or quantitative real-time reverse transcription (RT)–PCR. Interestingly, only
CD158k/KIR3DL2 transcripts were found to be significantly overexpressed in skin biopsies from patients with SS
(Po0.0001), including when normalization to CD3 expression was achieved (P¼ 0.0003). In light of these
findings, CD158k/KIR3DL2 transcripts appear to be a unique molecular marker of SS in skin samples, allowing
differential diagnosis with benign EID in routine practice.
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INTRODUCTION
Erythroderma is a severe dermatological condition, which
may result from different causes, including cutaneous T-cell
lymphoma, especially Se´zary syndrome (SS), and several
erythrodermic inflammatory diseases (EID), mostly psoriasis,
drug eruptions or atopic dermatitis (Pal and Haroon, 1998;
Akhyani et al., 2005; Rym et al., 2005). In the clinical setting
of erythroderma, the identification of an underlying cause is
difficult in practice, since clinical and histopathological
aspects are most often not enough specific. It is necessary to
differentiate benign EID from SS, which is an aggressive
lymphoma that requires an early and appropriate manage-
ment (Willemze et al., 2005). SS is characterized by the
presence of a malignant CD4þCD45ROþ T-cell clone that
localizes in both the blood and skin. In SS, cutaneous and
circulating malignant cells can be roughly identified by
morphological analyzes. Circulating Sezary cells however
are not specific for the diagnosis of SS (Vonderheid et al.,
1985) and histopathologically, atypical epidermotropic
T cells, when present, are sometimes difficult to identify in
skin biopsies. The identification of a monoclonal T-cell
population can provide diagnostic information (Wood et al.,
1994; Gorochov et al., 1995; Curco et al., 1997; Witzens
et al., 1997; Guitart and Kaul, 1999), which, however, is not
fully specific (Delfau-Larue et al., 2000). Besides the lack of
CD26 expression (Bernengo et al., 2001; Jones et al., 2001;
Scala et al., 2002) and CD7 (Rappl et al., 2001), we have
described new cell surface markers of malignant Se´zary cells
(Bagot et al., 2001; Huet et al., 2006). Among them, CD158k/
KIR3DL2, a killer immunoglobulin-like receptor normally
expressed by minor subsets of circulating T CD8þ lympho-
cytes and natural killer (NK) cells (Moretta et al., 1997),
readily allows the identification of the malignant T cells in the
blood of SS patients (Poszepczynska-Guigne et al., 2004;
Ortonne et al., 2006).
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Recent studies based on genomic and cDNA microarray
technologies have identified new molecular markers of
Se´zary cells, such as JUNB gene amplification and over-
expression (Mao et al., 2003, 2004), NAV3 gene deletion
(Karenko et al., 2005), and abnormal expression of various
markers at the transcript and/or protein level, such as Twist
and EphA4 (Kari et al., 2003; Nebozhyn et al., 2006). Among
them, T-plastin is a member of the fimbrins/plastins family,
which are highly conserved actin bundling proteins. T-plastin
is not expressed by normal lymphocytes under physiological
conditions and was therefore proposed as a specific
molecular marker for neoplastic lymphocytes in SS, but, to
the best of our knowledge, was not investigated in lesional
skin (Su et al., 2003).
Importantly, only few studies to date have focused on
cutaneous samples, so that a specific marker for SS in skin
biopsies is still lacking. Although KIR3DL2/CD158k actually
delineates the malignant clonal T-cell population in SS (Bagot
et al., 2001; Poszepczynska-Guigne et al., 2004; Ortonne
et al., 2006) and is expressed at the protein level by
lymphocytes in erythrodermic skin of patients with SS
(Wechsler et al., 2003), it is not known whether it may help
for the diagnosis of erythroderma in skin biopsies. To address
this issue, we analyzed the expression of CD158k/KIR3DL2 at
both protein and transcript levels, in a panel of skin biopsies
from patients with erythroderma from various causes, and we
compared the results obtained in SS versus benign EID.
RESULTS
Immunohistochemistry with AZ158 mAb did not clearly
discriminate between SS and benign EID
We observed a sub-epidermal band-like or mostly peri-
vascular lymphocytic infiltrate in all 40 skin samples from the
SS and the EID groups, associated with epidermotropic
lymphocytes in 85%. The density of dermal T-cell infiltrates
was categorized as þ , þþ , and þþþ in 0 (0%), 8 (57%),
and 6 (43%) samples from the SS group, respectively, and in
11 (42%), 12 (46%), and 3 (12%) samples from the EID
group, respectively. This indicated a higher lymphocytic
infiltration in SS, as shown in the cutaneous sample of patient
8 in Figure 1c. As previously reported (Wechsler et al., 2003),
immunohistochemistry with AZ158 mAb was positive in all
skin biopsies from patients with SS (Figure 1e), in agreement
with CD158k/KIR3DL2 expression. However, with AZ158
mAb, we also found positive cells in 17 biopsies of the EID
group (65%), as shown in Figure 1f, showing representative
sections of a patient with erythrodermic psoriasis. Mean
AZ158/CD3 ratios were similar in both groups in the
epidermis. However, in EID, we found a lower staining with
AZ158 mAb in the dermis, with 33% of SS samples versus
74% of EID samples showing a AZ158/CD3 ratio o25%,
(Student’s t-test, P¼0.0045). SS displayed lower CD8/CD3
ratios in both the epidermis and the dermis. Indeed, the mean
CD8/CD3 ratio was 12% in SS versus 38% in EID (Student’s
t-test, P¼0.003) in the epidermis. In the dermis, semi-
quantitative evaluation revealed that 83% of SS versus 38%
of EID samples had a CD8/CD3 ratioo25% (Student’s t-test,
P¼0.004). This latter finding is in agreement with the
preferential intra-epidermal localization of malignant CD4þ
lymphocytes in epidermotropic cutaneous T-cell lymphoma
such as SS and mycosis fungoides, whereas many reactive
CD8þ lymphocytes are present in the dermis (Bagot et al.,
1992; Ortonne et al., 2003). In addition, in all investigated
cases, we did not find CD56þ lymphocytes (data not shown),
indicating that NK cells were not predominant within the
infiltrates. Altogether, these results indicated that a higher
T-cell infiltration was present in SS than in EID skin samples,
and that differential diagnosis between SS and EID can not be
achieved reliably using immunohistochemistry with AZ158
mAb on frozen skin sections.
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Figure 1. Immunohistochemistry results for CD3 and CD158k/e (AZ158
mAb) in representative SS and EID skin samples. Histology, CD3 and AZ158
mAb stainings in cutaneous biopsies from (a, c, and e) the representative SS
patient 8, and from (b, d, and f) a patient with erythrodermic psoriasis.
(a and b) Hematoxylin and eosin-stained sections show in both samples a
sub-epidermal band-like lymphocytic infiltrate associated with scattered
epidermotropic lymphocytes. (c and d) CD3þ T cells are seen, but (c) a higher
T-cell infiltrate is present in the SS sample, associated with Pautrier
micro-abscesses (arrow). (e) Lymphocytes stained with AZ158 mAb are
seen in both the dermis and the epidermis in the SS sample, and also (f) in
a significant proportion of dermal lymphocytes (arrows) in the
erythrodermic psoriasis cutaneous sample. Slides are shown at original
magnification  200 (a and b) and  400 (c–f). Bar¼ 0.1mm.
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CD158k/KIR3DL2 transcripts were significantly overexpressed
in SS versus benign EID skin samples
Using conventional reverse transcription (RT)–PCR CD158k/
KIR3DL2 transcripts were readily detected in all but one
biopsy from the SS group (89%), whereas significant
expression of CD158k/KIR3DL2 mRNA could not be
evidenced in any sample from the EID group. Representative
results from conventional RT–PCR are shown in Figure 2.
Using this technique, a distinct bright band could be
visualized on agarose gel electrophoresis in 8/9 biopsies
from the SS group (Figure 2b, middle and right panels), with a
similar expression to normal NK cells and OGU Se´zary cell
line (Figure 2a, left and middle panels). By contrast, a
negative result or nonspecific bands was obtained in all
samples from the EID groups (Figure 2b, left panel). CD158e/
KIR3DL1 mRNA were not detected in both the SS and EID
groups (Figure 2b).
Using quantitative RT–PCR, CD3 mRNA expression was
detected in both SS and EID skin samples, indicating the
presence of a significant subset of T lymphocytes within the
cutaneous infiltrate in both groups (Figure 3a, left panel). We
found a slight CD3 transcript overexpression in SS samples
(Mann–Whitney’s test, P¼0.0133), in agreement with results
of morphological analyzes indicating that T-cell infiltration
was higher in the SS group. Using quantitative RT–PCR, we
found, with a different set of primers specifically designed for
the study (Table S2, lower portion), that CD158k/KIR3DL2
mRNA were readily detected in all but one SS skin sample,
with a significant overexpression when compared to samples
from the EID group (Mann–Whitney’s test, Po0.0001), as
shown in the middle panel in Figure 3a. In EID skin samples,
CD158k/KIR3DL2 mRNA appeared to be either undetectable
(n¼6, 60%) or expressed at very low levels (n¼4, 40%) as
for one sample from the SS group (patient 7; Figure 3b, left
panel), so that quantification was considered inappropriate,
due to the presence of nonspecific products on control
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Figure 2. Conventional RT–PCR amplification of CD158e/KIR3DL1 and
CD158k/KIR3DL2 in erythrodermic skin samples. (a) Controls. In natural
killer lymphocytes from a healthy donor, used as a positive control, both
CD158e/KIR3DL1 and CD158k/KIR3DL2 transcripts are found (left), whereas
in the Se´zary cell line OGU, only CD158k/KIR3DL2 appears to be positive
(middle). By contrast, in normal skin used as a negative control, both CD158e
and CD158k RT–PCR are negative (right). (b) Skin biopsies from patients with
erythroderma. In the skin sample from the EID group, neither CD158e/
KIR3DL1 nor CD158k/KIR3DL2 mRNA expression is detected (left).
By contrast, in the two SS samples (middle and right), a significant expression
of CD158k/KIR3DL2 is found, with a bright distinctive band at the expected
size, whereas CD158e/KIR3DL1 transcript are not detected.
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Figure 3. Quantitative RT–PCR amplification of CD3, CD158k/KIR3DL2 and T-plastin in erythrodermic skin samples. Activated peripheral blood
mononuclear cells from a healthy control donor were used as a calibrator and arbitrarily set as a CD3, CD158e/KIR3DL1, CD158k/KIR3DL2 and T-plastin
expression level of 1. The middle bar in each group represents the median of that group. (a) The median level of CD3 is higher in the SS group (P¼ 0.0133) (left).
CD158k/KIR3DL2 mRNA expression is highly overexpressed in SS versus EID skin samples (Po0.0001) (middle). By contrast, T-plastin transcript quantification
is not discriminant between SS and EID (P¼0.8421) (right). (b) Raw data (relative transcript expression 100), showing a significant overexpression of
CD158k/KIR3DL2 mRNA, but not T-plastin in SS (left) versus EID (right) skin samples. All data points represent the average of duplicate tests.
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agarose gel electrophoresis. CD158e/KIR3DL1 transcripts
were undetectable in both the SS and the EID groups (data
not shown). To avoid a possible misinterpretation related to
the higher T-cell infiltration found in SS skin samples, we also
evaluated the CD158k/CD3 ratio of relative mRNA copy
number, which remained significantly higher in the SS versus
the EID group (Mann–Whitney’s test, P¼0.0003).
Interestingly, in patient 1, we could detect CD158k
transcripts in a skin sample taken at a pre-erythrodermic
stage of the disease. This patient had erythematous and
squamous plaques with only few circulating CD158k/
KIR3DL2þCD4þ T cells and further showed development
of erythroderma. Patients 6 and 4 were evaluated at the stage
of partial remission under treatment (Table S1). Patient 6
partially responded to interferon a with persistent erythema-
to-squamous plaques. In this patient, CD158k/KIR3DL2
expression could be demonstrated using AZ158 immunos-
taining and RT–PCR studies, indicating that malignant T cells
were present in the skin, whereas only few Se´zary cells could
be detected in the blood. Patient 4 had TNM stage IV
disseminated disease, and was evaluated after he was placed
under systemic polychemotherapy (patient 4; Table S1).
At this stage, no circulating CD4þCD158k/KIR3DL2þ cells
were detected in the blood, in agreement with successful lysis
of tumoral cells by efficient chemotherapy, but he had a slight
persistent erythroderma. Interestingly, AZ158 stained cells
together with a positive RT–PCR for CD158k/KIR3DL2 were
found in the skin from this patient. These results suggested
that although malignant T cells could not be detected in the
blood, viable tumoral cells were present in the skin.
Altogether, these findings show that the detection of
CD158k/KIR3DL2 transcripts in the skin allows distinguishing
SS from benign erythrodermic inflammatory dermatoses, thus
indicating that CD158k/KIR3DL2 is a reliable molecular
marker of SS in skin samples. Furthermore, results obtained in
patients 1, 4, and 6 suggest that CD158k/KIR3DL2 mRNA
detection in the skin may allow diagnosis of SS even at pre-
erythrodermic early stage and may help in the detection of
residual disease under treatment.
T-plastin transcripts expression was not significantly higher in
SS versus benign EID skin samples
T-plastin, a member of the fimbrin/plastin family normally
expressed at low levels by non-hematopoietic mesenchymal
and epithelial tissues (Lin et al., 1993), has been recently
shown to delineate circulating malignant Se´zary cells
(Su et al., 2003). Although T-plastin is expected to be
expressed in normal skin, we sought to verify whether it
might be overexpressed in erythrodermic skin of SS patients,
due to infiltration of T-plastin expressing neoplastic lympho-
cytes. Using quantitative RT–PCR, we found that T-plastin
transcripts were detected at similar levels in cutaneous
samples from the SS and the EID group, as shown in the
right panel in Figure 3a (Mann–Whitney’s test, P¼0.8421).
The T-plastin/CD3 relative mRNA copy number ratio
appeared to be slightly more elevated in the EID group, but
the difference was not statistically significant (Mann–Whit-
ney’s test, P¼0.02). These results suggest that, contrasting
with CD158k, T-plastin is not a reliable molecular marker for
the diagnosis of SS in skin biopsies.
CD158k/KIR3DL2 alternatively spliced variants were not
detected in skin samples of benign EID
In the present study, we obtained in some skin samples
conflicting results with immunohistochemistry and RT–PCR,
regarding CD158k/KIR3DL2 expression. Indeed, immuno-
reactivity with AZ158 mAb was found within lymphocytic
infiltrates of a proportion of EID, while we could not detect
significant expression of CD158k/KIR3DL2 transcript in the
same skin specimen. One hypothesis is that non-neoplastic
reactive lymphocytes in erythrodermic skin from patients
with benign dermatoses may express alternative splicing
variant of CD158k/KIR3DL2, lacking one or both of the
exonic domains of primer hybridization. To address this
issue, we designed three additional sets of primers,
allowing amplification of three distinct CD158k/KIR3DL2
transcript segments located within exons 3–5, 4–9, and 8–9
(Table S2; Figure 4). Using all three sets of primers, negative
results were constantly obtained in all four EID samples
analyzed, as well as in normal skin used as a negative
control. By contrast, we could detect a distinct band of the
expected size on agarose gel electrophoresis in both skin
samples from patient 3 and Sezary cell line OGU, used as a
positive control. These findings indicate that the negative
results obtained with both conventional and quantitative
RT–PCR regarding CD158k/KIR3DL2 mRNA expression in
the EID group were not due to alternative splicing of CD158k/
KIR3DL2 transcripts.
Extracellular immunoglobulin-like domain Intracellular domain
11 aa 12 aa 95 aa 100 aa
Exons 4–5 (quantitative PCR) : 385 bp
Exons 4–5 (conventional PCR) : 369 bp
Exons 4–9 : 841 bp
Exons 8–9 : 242 bp
Exons 3–5 : 732 bp
Exons 3–9 : 1,188 bp
98 aa 17 aa 35 aa 18 aa 69 aa
987654321
ITIM
Figure 4. KIR3DL2 gene, RT–PCR products, and primers localization. Relative positions of the different cDNA segments (bottom) across the nine exons
of the KIR3DL2 gene (top), amplified according to the different sets of primers used for conventional and quantitative RT–PCR.
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DISCUSSION
Histopathological diagnosis of SS is often difficult, unless
distinct atypical epidermotropic T cells are identified. It is
hampered by its morphologic similarity to inflammatory
dermatoses, and the low proportion of tumoral cells, which
often account for a minority of the total tissue cells. In
addition, with the exception of Twist and EphA4 transcripts
(van Doorn et al., 2004), none of the newly described
molecular markers of malignant Se´zary cells has been
evaluated in skin samples. We have previously demonstrated
that CD158k/KIR3DL2 allows the identification of malignant
Se´zary cells in the blood, but the diagnostic importance of
this marker in the diagnosis of erythroderma in skin specimen
has never been studied. In the present study, expression of
CD158k/KIR3DL2 was analyzed at both protein product and
transcriptional levels in a series of frozen skin biopsies from
patients with erythroderma. Since AZ158 mAb, which
recognizes both CD158k/KIR3DL2 and CD158e/KIR3DL1,
was used for immunohistochemical procedures, both trans-
cripts were analyzed by molecular studies on the same skin
specimen. Unexpectedly, we found that, although constantly
positive in SS samples, immunohistochemistry using AZ158
mAb in frozen skin sections did not adequately discriminate
between SS and EID. Immunoreactivity to AZ158 mAb was
actually demonstrated in a significant proportion of benign
inflammatory erythrodermas, suggesting that CD158k/
KIR3DL2þ and/or CD158e/KIR3DL1þ cells are recruited in
the skin in erythrodermic inflammatory conditions. In
cutaneous T-cell lymphoma, we have shown that CD158k/
KIR3DL2 is specifically expressed by the malignant clonal
T-cell population in SS (Poszepczynska-Guigne et al., 2004;
Ortonne et al., 2006), whereas it is not expressed in plaque-
stage mycosis fungoides, which appear to be mostly negative
for CD158k/e immunostainings with AZ158 mAb (Wechsler
et al., 2003). Under physiological conditions, NK lympho-
cytes and minor subsets of CD8þ T cells may express killer
cell immunoglobulin-like receptors (KIRs) (Moretta et al.,
1997). It is therefore tempting to hypothesize that positive
cells in the EID group corresponded to normal lymphocytes
expressing CD158k/KIR3DL2 and/or CD158e/KIR3DL1. The
higher CD8/CD3 ratios and the constant negativity of CD56
staining obtained in the EID group support the hypothesis that
these cells might be indeed reactive CD8þ T lymphocytes.
Unfortunately, because we primarily conducted a retro-
spective study, we lacked blood material in most cases. Thus,
quantification of the CD158k/KIR3DL2þ and CD158e/
KIR3DL1þ subsets within the circulating CD4þ and CD8þ
T-cell populations with flow cytometry could not be
performed in most cases, except for three patients out of
the SS group, in which CD158kþ T cells were identified in
the blood. Surprisingly, using both conventional and quanti-
tative RT–PCR experiments, we found a significant over-
expression of CD158k/KIR3DL2 transcripts in skin samples of
the SS versus the EID group. By contrast, quantitative RT–PCR
experiments revealed that the level of T-plastin expression
was similar in both groups. This result probably reflects that
other, non-lymphoid, cells express T-plastin in the skin, in
agreement with its known synthesis by a wide variety of non
hematopoietic epithelial and non epithelial cells (Lin et al.,
1993). As we found evidences that SS had a higher T-cell
infiltration than EID, CD158k/KIR3DL2 and T-plastin relative
mRNA expression was normalized to CD3, which still
showed a significant overexpression of the former in the SS
group. In this series, using specific transcripts detection and
quantification, CD158k/KIR3DL2 thus appeared to be a
unique molecular marker of SS in the skin, contrasting with
immunohistochemistry with AZ158 mAb and T-plastin
mRNA quantification, which were not discriminant enough
between SS and benign EID. Two patients from this series
were evaluated at the stage of partial remission under
treatment. One partially responded to interferon a with
persistent erythemato-squamous plaques, whereas the other
had advanced disease and was evaluated after being placed
under systemic polychemotherapy. In skin biopsies of these
patients, CD158k/KIR3DL2 expression could be demons-
trated using AZ158 immunostaining and RT–PCR assays,
whereas no or few Se´zary cells could be detected in the
blood. This finding suggested that although malignant T cells
could not be detected in the blood, viable tumor cells were
still present in the skin. In light of these results, it is tempting
to speculate that the skin may represent a sanctuary site for
neoplastic cells in patients placed under systemic therapies.
In agreement with this hypothesis, Assaf et al. (2004) have
recently reported a patient with erythrodermic SS, which
turned into plaque-stage disease and then high-grade T-cell
lymphoma during treatment with extracorporeal photophere-
sis, whereas clearance of circulating Se´zary cells was
obtained. They however found an identical dominant T-cell
clone in the skin at all stages, suggesting that malignant cells
were still present in the skin under treatment, and further
transformed in situ. In this context, we can ask whether
CD158k/KIR3DL2-specific RT–PCR performed on skin biop-
sies could be a unique tool for the evaluation of residual
disease under treatment.
Interestingly, in one patient with SS, we could detect
CD158k/KIR3DL2 transcripts in a skin sample obtained at a
pre-erythrodermic stage of the disease. Initially, this patient
presented with erythematous and squamous plaques with
only few circulating CD158k/KIR3DL2þCD4þ T cells, so
that a diagnosis of mycosis fungoides was proposed. She
further developed erythroderma with atypical CD158k/
KIR3DL2þ circulating Se´zary cells, allowing diagnosis of
SS. This result suggests that CD158k/KIR3DL2 mRNA might
be used as an early marker for SS, allowing identification of
the malignant cells in the skin before development of
erythroderma. Further studies are however needed to
determine whether CD158k/KIR3DL2 mRNA expression
may be used to differentiate early plaque-stage SS from
mycosis fungoides, characterized by an indolent course.
It is important to note that conflicting results were
obtained with immunohistochemistry and RT–PCR, in some
cases from the EID group regarding CD158k/KIR3DL2
expression. AZ158 mAb indeed labeled the lymphocytic
infiltrates in a proportion of cases, whereas CD158k/KIR3DL2
transcripts appeared to be either undetectable or expressed at
such a low level that reliable quantification was not possible.
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CD158e/KIR3DL1 transcripts were not found in any investi-
gated case, thus ruling out the hypothesis that AZ158-labeled
cells could be mostly CD158e/KIRDL1þ lymphocytes. We
also conducted additional molecular studies in representative
cases, which excluded the possibility that alternative splicing
variants of CD158k/KIR3DL2, with skipping of an exonic
domain of primer hybridization, were expressed in erythro-
dermic inflammatory conditions. Further studies are needed
to determine whether infiltrating lymphocytes in benign
erythrodermic dermatoses may express very low levels of
KIRs transcripts, as compared to malignant Se´zary cells, or
may transiently activate the transcription of KIRs before
recruitment in the skin. In agreement with this latter
hypothesis, the heterogeneous expression of some KIRs
within an identical T-cell clone has been previously reported
in normal T cells (Vely et al., 2001), and, similarly, we have
reported heterogeneous expression of CD158k/KIR3DL2
within a malignant Se´zary T-cell clone (Ortonne et al.,
2006). These findings indeed indicate that KIRs expression in
T cells can occur at a mature stage of differentiation, after
TCR rearrangements, and further suggest that KIR expression
may be positively and/or negatively regulated in these cells.
In conclusion, the detection of significant levels of
CD158k/KIR3DL2 transcript using quantitative RT–PCR in
erythrodermic skin allows diagnosis of SS, even in very early
stages of the disease, and represents a reliable marker of the
disease in skin samples. This molecular marker can be easily
used in routine practice to perform differential diagnosis
between erythrodermic benign inflammatory dermatoses and
SS, which requires early and specific management.
MATERIALS AND METHODS
Patient selection, control cases, and cells
Thirteen frozen biopsy samples from 10 patients with SS were
retrieved from the files of the Department of Pathology of our
institution (Hoˆpital Henri Mondor, Cre´teil). The clinical features of the
patients with SS are shown in Table S1. There were four females and
six males, with a median age of 71 years (range 61–79 years). In these
patients, SS was diagnosed according to the current WHO-EORTC
classification (Willemze et al., 2005), and following the criteria
defined by Russell-Jones (2005). Among these criteria, a T-cell clone
could be evidenced in both the skin and blood of all patients from the
SS group. In addition, CD158k/KIR3DL2 expression by peripheral
blood lymphocytes could be demonstrated in three patients out of the
SS group (patients 1, 2, and 3; Table 1) using flow cytometric studies,
as described previously (Poszepczynska-Guigne et al., 2004; Ortonne
et al., 2006). Two SS patients were investigated at the time of partial
remission, with no or few circulating Se´zary cells: patient 4 had slight
persistent erythroderma without circulating Se´zary cells after a
first round of polychemotherapy, and patient 6 had persistent
erythematous plaques under interferon a treatment. In the former,
polychemotherapy was introduced because the patient had stage IV
progressive disease with multiple large adenopathies.
As control samples, we selected skin biopsies from 26
erythrodermic patients (10 females and 16 males; mean age, 67
years), with a diagnosis of non-lymphomatous, benign EID:
erythrodermic psoriasis (n¼ 8), drug eruption (n¼ 10 including
one with acute generalized exanthematic pustulosis and three with
drug-induced hypersensitivity syndrome), eczema (n¼ 3), pityriasis
rubra pilaris (n¼ 1), myelodysplastic syndrome (n¼ 1), primary
hypereosinophilic syndrome (n¼ 1), and unspecified erythroderma
(n¼ 2). T-cell clonality results were available in only four patients
from the EID group. Among these four EID patients, a dominant
T-cell clone was found in the skin in one and in the blood in another.
Normal skin samples and NK lymphocytes from healthy donors
as well as the Se´zary cell lines Pno, previously established in our
laboratory (Poszepczynska et al., 2000), and OGU, recently
developed (Marie-Cardine et al., 2007), were used as controls for
molecular studies. NK lymphocytes were isolated from peripheral
blood of a healthy donor using the magnetic-activated cell sorter NK
cell isolation kit (Miltenyi Biotec, Auburn, CA), following the
manufacturer’s instructions.
This study was approved by the Comite´ Consultatif de Protection
des Personnes dans la Recherche Biomedicale institutional ethics
committee. Informed consent was provided according to the
declaration of Helsinki Principles.
Immunohistochemistry and evaluation of the CD8/CD3 and
AZ158(CD158k/e)/CD3 ratios
For immunostaining procedure, 5-mm-thick frozen sections were
placed on Superfrost plus slides (CML, Angers, France), air dried
overnight, and fixed in acetone for 10minutes before storing at
–201C. Slides were post-fixed in acetone for 5minutes and air dried
before use. The immunostaining procedure was performed after
rehydration in Tris/NaCl buffer. CD158k/KIR3DL2 expression was
analyzed using the purified IgG2a AZ158 mAb (Innate Pharma,
Marseille, France), which also recognizes the monomeric receptor
CD158e/KIR3DL1 (Parolini et al., 2002). The anti-CD3, -CD4, -CD8,
and -CD56 mAbs were purchased from DAKO (DAKO SA, Glostrup,
Denmark). All primary mAbs were used at a 1:50 dilution. We used
an incubation period of 4 hours for AZ158, and 1 hour for all other
primary mAbs, at room temperature. The staining was performed
using a biotinylated secondary antibody and avidin conjugated to
alkaline phosphatase (vectastain ABC–AP kit from Vector, Burlin-
game, CA). The alkaline phosphatase reaction was detected by
Naphtol-Fast Red (Sigma-Aldrich, Saint Quentin Fallavier, France)
and sections were counterstained in blue with hematoxylin. As a
control for immunostaining with AZ158 mAb, we used frozen
sections of normal spleen, where a subset of the scattered CD56þ
NK cells normally present is expected to express CD158e/KIR3DL1
and/or CD158k/KIR3DL2.
In all samples, we categorized the density of dermal T-cell
lymphocytic infiltrates into three groups : þ scattered lymphocytes,
þþ clusters of lymphocytes, and þþþ dense and diffuse
infiltration, according to CD3 staining. Epidermal and dermal
lymphocytic infiltrates were separately analyzed. In the epidermis,
the number of CD3þ , CD4þ , CD8þ , and AZ158þ cells was
counted on the total epidermal length. In the dermis, a semi-
quantitative analysis was performed, in which we categorized the
CD4/CD3, CD8/CD3, and AZ158/CD3 ratios into four groups:
1 (0–25%), 2 (425–50%), 3 (450–75%), and 4 (475–100%).
RT–PCR amplification of CD3, CD158k/KIR3DL2,
CD158e/KIR3DL1, and T-plastin transcripts
Molecular studies were performed on the same frozen skin sample
used for immunohistochemistry in nine specimens from eight
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patients out of the SS group, and in 10 specimens out of the EID
group. As controls for molecular studies, we used total mRNA
extracted from normal skin and NK lymphocytes of healthy donors
and from the Se´zary cell lines Pno (Poszepczynska et al., 2000),
previously established in our laboratory, and OGU, developed
recently (Marie-Cardine et al., 2007).
For total RNA extraction from skin samples, twenty 50-m-thick
frozen sections were transferred into Trizol and immediately
homogenized twice for 2minutes with a Mixer Mill MM301 (Verder,
Erahny sur Oise, France) before chloroform/isopropanol precipita-
tion. Total mRNA was then reverse transcribed by using oligo-dT
primers and Powerscript reverse transcriptase (RT Clontech, Palo
Alto, CA).
Amplification of CD158k, CD158e and b-actin transcripts using
conventional PCR was performed as previously described (Uhrberg
et al., 1997), with amplification conditions as follows: initial
denaturation at 951C for 2minutes; then 60 seconds at 621C for
hybridization, 45 seconds at 721C for elongation, and 60 seconds at
941C for next steps denaturation, for the first five cycles, and then
45 seconds at 601C, 45 seconds at 721C and 30 seconds at 941C for
30 cycles. We used previously reported primers for CD158k/
KIR3DL2 and CD158e/KIR3DL1 (Uhrberg et al., 1997), as well as
for b-actin (Ju et al., 1999), used as a positive control. Regarding
CD158k/KIR3DL2, additional sets of primers were used, in order to
search for alternatively spliced transcripts, allowing amplification of
mRNA segments located with exons 3–5, 4–9, and 8–9, as shown in
Figure 4. The sequence and positions of all primers used for
conventional PCR are provided in Table S2 (upper part).
Quantitative PCR reactions for CD3 (delta chain), CD158k,
CD158e, and T-plastin were performed with a LightCycler 2.0
System (Roche Diagnostics, Meylan, France), using a SYBR Green
PCR kit from Roche Diagnostics (Meylan, France). Melting curves
and agarose gel electrophoresis established the purity of the
amplified product. Normalization was achieved by quantification
of the mRNA expression of the SF3A1 gene, encoding for the
120 kDa subunit of the splicing factor 3a (Tanackovic and Kramer,
2005), chosen as control housekeeping gene (Szabo et al., 2004) for
its stable expression in lymphocytes, as previously described (Mesel-
Lemoine et al., 2006). PCR samples contained 4mM MgCl2, 0.4 mM of
each primer, and amplification cycling conditions were as follows:
941C for denaturation, 10 seconds at 601C for hybridization and
25 seconds at 721C for elongation for 40 cycles. The expression of
transcripts was measured by the relative quantification of real-time
PCR, as previously described (Gibson et al., 1996). As calibrator
samples, we used peripheral blood mononuclear cells from healthy
control donors activated for 1 hour with phorbol ester and
ionomycin (5 and 1ng/ml, respectively) for CD3, CD158k,
CD158e, and a liver specimen for T-plastin. All PCR conditions
were adjusted in order to obtain equivalent optimal amplification
efficiency between the different assays. By using the obtained linear
graphs, the differences in Ct values were determined for each sample
and were expressed as relative percentage of mRNA present in the
calibrator sample, according to the DDCt method, after adjustment of
PCR efficiency with the Light Cycler software 4.0 (Roche, Meylan,
France). Quantification was considered to be unreliable when the
presence of nonspecific products was detected on the control
agarose gel. In these cases, the relative percentage of transcripts was
arbitrarily set as 0.1. All PCR experiment were performed in
duplicate. The sequence and positions of primers used for
quantitative PCR are provided in Table S2 (lower part).
T-cell clonality analysis
For T-cell clonality studies, DNA was extracted from a different
snap-frozen skin biopsy and analyzed by DNA amplification of the
T-cell receptor-gamma gene using consensus primers and separation
of the amplimers on denaturing sequencing gel (PCR-denaturing
gradient gel electrophoresis), as previously described (Theodorou
et al., 1995).
Statistical analysis
Student’s t-test was used to compare the mean epidermal and dermal
CD8/CD3 and AZ158/CD3 ratios between samples from the SS and
the control EID groups. The non-parametric Mann–Whitney’s test
was used because of the non-normal distributions of mRNA levels
differences of CD3, CD158e/KIR3DL1, CD158k/KIR3DL2, and
T-plastin expression between the SS and the EID specimens.
Following Bonferroni correction for multiple testing with quantita-
tive RT–PCR, differences were considered to be statistically
significant when Po0.01.
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